Regeneron Pharmaceuticals, Inc. (REGN)

業務介紹

Regeneron Pharmaceuticals, Inc.（再生元制藥公司）在全球範圍內發現、發明、開發、製造和商業化用於治療各種疾病的藥物。該公司的產品包括EYLEA注射劑，用於治療濕性年齡相關性黃斑變性和糖尿病性黃斑水腫；近視性脈絡膜新生血管；糖尿病視網膜病變，以及視網膜靜脈阻塞後的黃斑水腫，包括中央視網膜靜脈阻塞後的黃斑水腫和分支視網膜靜脈阻塞後的黃斑水腫。它還提供Dupixent注射劑，用於治療成人和兒童的特應性皮炎和哮喘；Libtayo注射劑，用於治療轉移性或局部晚期皮膚鱗狀細胞癌；Praluent注射劑，用於治療成人的異型家族性高膽固醇血症或臨床動脈粥樣硬化心血管疾病；REGEN-COV用於新冠肺炎；以及Kevzara溶液，用於治療成人的類風濕性關節炎。此外，該公司還提供Inmazeb注射劑，用於治療由薩伊爾伊博拉病毒引起的感染；ARCALYST注射劑，用於治療與冷凍蛋白相關的週期性綜合徵，包括家族性寒冷自身炎症綜合徵和馬克爾韋爾斯綜合徵；以及ZALTRAP注射劑，用於靜脈輸注治療轉移性結腸直腸癌；並開發用於治療眼科、過敏和炎症、心血管和代謝、傳染性和罕見疾病；以及癌症、疼痛和血液學疾病的產品候選藥物。該公司與Sanofi、拜耳、Teva製藥工業有限公司、三菱產藥株式會社、Alnylam製藥公司、羅氏製藥和Kiniksa製藥有限公司簽訂了合作和許可協議，並與美國衛生和人類服務部以及Zai Lab有限公司、Intellia Therapeutics公司、生物醫學先進研究發展局和阿斯利康有限公司簽訂了協議。該公司成立於1988年，總部位於紐約州塔里敦。

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma;Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services, as well as with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.

公司網址

https://www.regeneron.com